Andrew R. Tee

Heath Park Way
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Ninth BHD International Symposium: Advancing research through global collaboration.

Ninth BHD International Symposium: Advancing research through global collaboration.

Journal: Cell stress & chaperones

Published: April 27, 2026

Correction: Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity.

Correction: Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity.

Journal: eLife

Published: February 12, 2026

Sweet signals for myelin: glucose sensing redirected to regeneration.

Sweet signals for myelin: glucose sensing redirected to regeneration.

Journal: Nature metabolism

Published: October 22, 2025

Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer Cells.

Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer Cells.

Journal: Cancers

Published: July 14, 2025

mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node.

mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node.

Journal: Orphanet journal of rare diseases

Published: November 06, 2024

Loss of Tuberous Sclerosis Complex 2 confers inflammation via dysregulation of Nuclear factor kappa-light-chain-enhancer of activated B cells.

Loss of Tuberous Sclerosis Complex 2 confers inflammation via dysregulation of Nuclear factor kappa-light-chain-enhancer of activated B cells.

Journal: Research square

Published: July 29, 2024

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome through transcriptiomic and proteomic analysis.

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome through transcriptiomic and proteomic analysis.

Journal: Research square

Published: July 09, 2024

Loss of tuberous sclerosis complex 2 confers inflammation via dysregulation of nuclear factor kappa-light-chain-enhancer of activated B cells.

Loss of tuberous sclerosis complex 2 confers inflammation via dysregulation of nuclear factor kappa-light-chain-enhancer of activated B cells.

Journal: Journal of inflammation (London, England)

Published: June 12, 2024

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome cell models through transcriptomic and proteomic analysis.

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome cell models through transcriptomic and proteomic analysis.

Journal: Oncogene

Published: May 31, 2024

Tuberous Sclerosis Complex cell-derived EVs have an altered protein cargo capable of regulating their microenvironment and have potential as disease biomarkers.

Tuberous Sclerosis Complex cell-derived EVs have an altered protein cargo capable of regulating their microenvironment and have potential as disease biomarkers.

Journal: Journal of extracellular vesicles

Published: October 07, 2022

Drug Inhibition of Redox Factor-1 Restores Hypoxia-Driven Changes in Tuberous Sclerosis Complex 2 Deficient Cells.

Drug Inhibition of Redox Factor-1 Restores Hypoxia-Driven Changes in Tuberous Sclerosis Complex 2 Deficient Cells.

Journal: Cancers

Published: September 08, 2022

Correction: Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.

Correction: Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.

Journal: British journal of cancer

Published: August 11, 2022

Showing 1-12 of 56

Last Updated: 09/26/2026